Julie C. Switzky

发表

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

J. Nemunaitis, J. Bendell, C. Borg, 2018, Cancer medicine.

Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies

David C. Smith, P. LoRusso, R. Kurzrock, 2019, Clinical Cancer Research.

Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.

C. Rudin, M. Socinski, Gregory Riely, 2013 .

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

A. Hauschild, D. Schadendorf, P. Ascierto, 2012, The Lancet. Oncology.

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors

D. V. Von Hoff, R. Donehower, G. Beatty, 2018, The oncologist.

A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.

J. Gschwend, A. Santiago-Walker, B. Tran, 2020 .

Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites

P. Haney, V. Goodman, D. Ouellet, 2014, Journal of clinical pharmacology.

A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,

R. Advani, J. Leonard, C. Hofmeister, 2010 .

Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.

J. Leonard, C. Hofmeister, A. Chanan-Khan, 2017, The Lancet. Haematology.

Break-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets)

A. Hauschild, D. Schadendorf, P. Ascierto, 2012 .

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

A. Hauschild, D. Schadendorf, P. Ascierto, 2012, The Lancet. Oncology.

Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.

J. Leonard, C. Hofmeister, A. Chanan-Khan, 2017, The Lancet. Haematology.

Preliminary Results from an Ongoing Phase 1/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with Advanced Malignancies

David C. Smith, P. LoRusso, R. Kurzrock, 2017 .

Efficacy/safety analysis of a phase 2 study of ruxolitinib (Rux) + regorafenib (Re) in patients (pts) with relapsed/refractory (r/r) metastatic colorectal cancer (mCRC).

J. Nemunaitis, J. Bendell, C. Borg, 2017 .